The Impact of Persistent Irritability on the Medication Treatment of Paediatric Attention Deficit Hyperactivity
Raman Baweja1, Daniel A Waschbusch1, William E Pelham2
1Department of Psychiatry and Behavioral Health, Penn State College of Medicine, Hershey, PA, United States.
Insights
Central nervous system stimulants effectively treat attention deficit hyperactivity disorder (ADHD) in children, even those with significant irritability. Higher medication use improved ADHD and oppositional defiant disorder symptoms in the irritability group.
Area of Science:
- Pediatric Psychiatry
- Neuroscience
- Pharmacology
Background:
- Attention deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
- Irritability is a frequently observed comorbidity in pediatric ADHD, impacting treatment outcomes.
- Central nervous system (CNS) stimulants are a primary pharmacotherapy for ADHD.
Purpose of the Study:
- To compare the efficacy and tolerability of CNS stimulants in children with ADHD, with and without prominent irritability (IRR).
- To analyze the impact of medication use on ADHD and comorbid symptoms in treatment-naïve youth.
Main Methods:
- Secondary analysis of a 30-month study on medication-naïve children with ADHD treated with CNS stimulants (primarily OROS-Methylphenidate).
- Children were categorized as IRR based on specific items from the Disruptive Behavior Disorders Rating Scale (DBDRS).
- Structured ratings of ADHD, oppositional defiant disorder (ODD), impairment, and side effects were collected regularly; medication use was tracked.
Main Results:
- The IRR group (28% of participants) showed higher baseline ADHD, ODD symptoms, impairment, and side effects.
- In the IRR group, higher medication use correlated with significant decreases in ODD symptoms, emotional lability, and impairment.
- Increased medication use led to higher overall side effects in non-IRR participants but decreased emotional side effects in the IRR group.
Conclusions:
- CNS stimulants are a tolerable and efficacious treatment for medication-naïve youth with ADHD, including those with prominent irritability.
- Higher medication adherence in the irritability subgroup is associated with improved behavioral and emotional regulation.
- Individualized treatment approaches considering irritability symptoms are crucial for optimizing ADHD management in children.
Abstract:
This study compares the efficacy and tolerability of central nervous system (CNS) stimulants in children with attention deficit hyperactivity disorder (ADHD) with and without prominent irritability (IRR) over the course of 30 months. This is a secondary analysis of a study examining growth patterns in medication naïve children with ADHD subsequently treated with CNS stimulants (predominantly OROS-Methylphenidate, up to 54 mg per day) for 30 months. Participants had to meet full diagnostic criteria for ADHD and been treated with CNS stimulants for under 30 days. Children were classified as IRR if they were rated as pretty much or very much on either of the "often angry" or easily annoyed" items plus "lose temper," items of the Disruptive Behavior Disorders Rating Scale (DBDRS). Structured ratings of ADHD symptoms, impairment, side effects, and symptoms of oppositional defiant disorder (ODD) were collected every 2-12 weeks for the duration of the study. Medication use was measured by pill count and parent report. The IRR group comprised 28% of all participants. The IRR group had significantly higher levels of ADHD and ODD symptoms, impairment, and side effects ratings at baseline. In the IRR group, ODD symptoms, emotional lability, and impairment significantly decreased for participants with higher medication use. Total side effects increased for non-IRR participants with higher medication use. Emotional side effects decreased for IRR participants with higher medication use. Central nervous system stimulants were a tolerable and efficacious treatment in treatment naïve youth with ADHD with irritability. Clinical Trials Registration: NCT01109849.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
01:24Mania and Antimanic Drugs: Overview
01:30Oppositional Defiant Disorder
Diagnostic Criteria and...
01:28Drug Therapy
Antianxiety Medications
01:19Autism Spectrum Disorder
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion